Lenalidomid Sandoz

Lenalidomide, the active ingredient in Lenalidomid Sandoz, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes with del(5q) in adult patients.

GNH USA supplies Lenalidomid Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company ensures quality, regulatory compliance and reliable logistics to support global cancer care delivery. Our distribution network reaches both public and private healthcare institutions across Europe, Asia and the Americas.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells. - Multiple Myeloma: improves progression‑free survival, overall response rate, and depth of response when combined with dexamethasone or proteasome inhibitors in adult patients. - Mantle Cell Lymphoma: incorporated into combination chemotherapy protocols to achieve disease control and prolong remission in relapsed or refractory adult patients. - Myelodysplastic Syndromes with del(5q): promotes transfusion independence, reduces red‑cell transfusion requirements, and can lead to cytogenetic remission in adult patients with the del(5q) chromosomal abnormality.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity. Common Side Effects: - Neutropenia: decreased neutrophil count, increasing infection risk and may require dose interruption. - Thrombocytopenia: reduced platelet levels, may cause easy bruising and bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities and quality of life. - Diarrhea: loose stools that may lead to dehydration and electrolyte imbalance. Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers unrelated to original disease. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating lenalidomide therapy, several precautions should be considered to ensure patient safety. - Pregnancy risk: drug is teratogenic; avoid use in pregnant women and ensure effective contraception. - Thromboembolic risk: assess need for prophylactic anticoagulation, especially when combined with dexamethasone. - Renal impairment: adjust monitoring and dosing in patients with reduced kidney function. - Hepatic dysfunction: evaluate liver function tests prior to treatment and monitor regularly. - Infection monitoring: watch for signs of infection due to neutropenia and provide prompt management. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting its efficacy or safety. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may significantly lower lenalidomide plasma concentrations, reducing therapeutic effect. - Anticoagulants (warfarin, direct oral anticoagulants): concurrent use can heighten bleeding risk, especially in the presence of thrombocytopenia. Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine, tacrolimus): may increase hematologic toxicity, requiring closer blood count monitoring. - CYP1A2 inhibitors (e.g., fluvoxamine): can cause modest elevation of lenalidomide levels, warranting dose review. - Live attenuated vaccines: immunomodulatory action may impair vaccine efficacy and increase infection risk. - P-glycoprotein substrates (e.g., digoxin): may experience altered clearance; monitor therapeutic levels.